© 2021 MJH Life Sciences and Cure Today. All rights reserved.
© 2021 MJH Life Sciences™ and Cure Today. All rights reserved.
July 05, 2021
The combination may offer patients with recurrent, platinum-agnostic ovarian cancer a more effective, non-platinum-based treatment option.
June 08, 2021
Patients with early triple-negative breast cancer receiving Imfinzi in addition to neoadjuvant chemotherapy saw increased survival rates and complete responses to treatment.
May 20, 2021
The use of Opdivo combined with the novel therapy relatlimab resulted in a significant improvement of progression-free survival compared to treatment with Opdivo, alone, in patients with previously untreated, unresectable or metastatic melanoma.
Imperfection After Breast Cancer
Using Group Therapy as a Learning Experience for Patients With Cancer
FDA’s Approval of Keytruda-Based Regimen for Certain Stomach Cancer Subtypes ‘Really Exciting’ For Patients
Heart Failure May Increase Cancer Risk